Intervet / Schering Plough Animal Health has launched Leventa, an easily administered once daily, liquid treatment for canine hypothyroidism.
Leventa is a low volume liquid formulation of levothyroxine sodium which provides the thyroxine needed by dogs with hypothyroidism. The company says it is readily accepted.
Until now, thyroxine has only been available in a tablet format. Leventa comes in a single presentation 30 ml bottle with a dosing syringe suitable for all weights of dogs, allowing straightforward storage and stock control.
Leventa enables accurate dosing and easy dose titration. The ready-to-dispense pack avoids time-consuming tablet dispensing and handling of medications.
In addition to the practical compliance benefits of the liquid format, Intervet / Schering Plough says Leventa also offers excellent bio-availability1. In trials, 79% of dogs stabilised on the once daily starting dose of 20g/kg avoiding lengthy stabilisation2.
Vicki Winslet, Veterinary Advisor at Intervet / Schering Plough said: "One of the greatest challenges faced by vets for effective treatment is owner compliance. Leventa overcomes this issue with a simple syringe dose replacing the need for tablets of varying sizes and quantities."
One of the most common endocrine disorders in dogs but difficult to diagnose, hypothyroidism can lead to a variety of issues including weight gain, lethargy and coat problems (including dullness, loss or thinning). It can also cause insulin resistance in diabetic dogs.
The launch of Leventa further extends Intervet / Schering Plough's endocrine portfolio which includes Caninsulin, developed for the treatment of diabetes in small animals and Vidalta, a once daily treatment for hyperthyroidism in cats which is already proving extremely popular with the profession.
For further information, please contact your Intervet/Schering-Plough account manager or telephone the company's Veterinary Support Group on 01908 685685.
1. Le Traon G, Burgaud S, Horspool LJ. (2008) Pharmacokinetics of total thyroxine in dogs after administration of an oral solution of levothyroxine sodium. J Vet Pharmacol Ther 31:95-101.2. Gommeren K, Benchekroun G, Brennan S.F, Burgaud S, Daminet S, Horspool L.J.I, Le Traon G, Rosenberg D, Mooney C.T (2008) A novel L-thyroxine solution is a safe and effective once daily treatment for canine hypothyroidism. In:Proceedings BSAVA congress 2008 , 3-6 April Birmingham, UK pp487-488
CEVA Animal Health, manufacturer of pheromonatherapy products, D.A.P.® and Feliway®, has launched a new website - http://www.petfireworkfear.co.uk/ - and a new leaflet and waiting room poster to support its ‘Remember, remember your pets this November' campaign which is backed by the PDSA, FAB (Feline Advisory Bureau), the APBC (Association of Pet Behaviour Counsellors) and Sound Therapy 4 Pets.
The website features a comprehensive range of information including hints and tips on preparing pets for the firework festivities, how to spot signs of stress in cats and dogs, what to do if pets go missing or are injured, fireworks and the law and information on pheromonatherapy.
"The new site is a one stop shop for information on how to look after pets during the firework season and the precautions that owners should take to help pets cope with their fear of loud noises," says Lucy Brett, product manager at CEVA Animal Health. "Veterinary practices can help highlight these precautions by linking their websites to the ‘Remember, remember your pets this November' site."
A downloadable PR toolkit is also available from the website to enable veterinary practices to highlight the campaign to local pet owners. To request a copy of the ‘Remember, remember your pets this November' information pack, which includes details on CEVA's ‘Promote Your Practice' competition, please call Lucy Brett at CEVA on 01494 781510.
Vets Now, the UK's dedicated Out Of Hours emergency vets with 32 clinics across the UK is launching a new recruitment initiative whereby vets with two years post qualified small animal experience have the opportunity to experience life working at the cutting edge of Emergency and Critical Care (ECC) through a range of new flexible short term contracts.
ECC represents a new, exciting and growing sector in the UK and Vets Now is offering vets a range of short to medium term flexible contracts which will enable you to develop new clinical skills in an exciting, fast paced environment. The contracts will appeal to any vet who is looking to gain experience working in ECC either with a view to pursuing a career in this specialised area or returning to daytime practice equipped with new clinical skills.
Speaking about the new contracts being offered, Fiona Dewar, HR Director for Vets Now SAid: "The nature of ECC medicine means that there is never a dull moment in our clinics and we tend to attract young, dynamic professionals who are keen to develop new clinical skills and have a more flexible working package. We know from experience that long term contracts don't appeal to everyone and we want to attract the best vets to come and work for us, whether it's for a three month contract or a twelve month contract with the added option of becoming permanent."
For more information about the range of contracts in one of Vets Now's 32 clinics, please contact Pauline Aitken, Vets Now Recruitment Manager on 0800 033 6466.
Fort Dodge, which supplies Bluetongue vaccine in continental Europe, has licensed its cattle vaccine in the UK and is now launching the product onto the UK market.
The company has already won and met tenders from several European governments, including France, Spain, Italy, Portugal Germany, Switzerland, Belgium and the Czech Republic for its Zulvac 8® Bovis vaccine and says it is the only international company to have produced vaccines for the most commonly occurring serotypes of the disease including 8, 4 and 1.
Approved by the VMD with a Provisional Marketing Authorisation, Zulvac 8 is available in 50 dose and 10 dose packs. The key claims are active immunisation against Bluetongue serotype 8 of cattle from 2.5 months old and a significant reduction of viraemia.
The vaccine is administered in 2 x 2 ml doses at three week intervals given by intra muscular injection and the product is supported by a fixed 2ml multidose applicator with Sterimatic needle protector and cleaning system to ensure accurate dosing and hygienic conditions.
John Hanley, Managing Director of Fort Dodge UK, said: "We were first to market with our Zulvac 8 product in three European countries and have received an Award for Agricultural Merit from the Spanish Government for our work in Bluetongue control. Following the licensing of Zulvac 8 Bovis in the UK we now have the opportunity to launch the product onto the UK market.
"In terms of pricing, Zulvac 8 is competitive per dose against other products in the market and it is supported by the experience gained in Europe with millions of animals already vaccinated. We're delighted that the VMD have authorised the vaccine and believe its availability can play a key role in protecting the UK's cattle from this dreadful disease."
The product is authorised for use by cattle farmers in the protection zone only, and will require veterinary prescription. Farmers can administer the vaccine to their cattle and the 2ml intra-muscular injection will be an advantage in aiding administration especially when used with Zulvac Bovis applicator with sterimatic needle protector and cleaning system.
The first batches will be available from veterinary wholesalers from week commencing 22nd September 2008.
The British Equine Veterinary Association (BEVA) welfare award 2008, sponsored by The Blue Cross, has been presented to the Retraining of Racehorses (RoR) organisation for their contributions to equine welfare in support of the re-training and re-homing of racehorses.
The award, which was introduced by BEVA in conjunction with The Blue Cross animal welfare charity eight years ago, is a formal recognition of significant contributions made by veterinary surgeons and others to equine welfare.
It was presented to Ron Huggins, trustee of the ROR and an owner and breeder of racehorses, at the 47th BEVA Annual Congress in Liverpool on Friday 12 September 2008, by Kerstin Alford, equine welfare director of The Blue Cross.
Kerstin said: "The financial support that RoR provides for charitable racehorse rehabilitation centres, together with their education programme to help owners and riders of former racehorses, make them very worthy recipients of this award."
Di Arbuthnot, director of operations said: "RoR are delighted to receive this prestigious award to recognise the work the charity does for former racehorses to provide them with a life after racing."
Retraining of Racehorses was established in 2000 by the British Horseracing Authority. Its aim is to raise funds from the British racing industry to provide and maintain facilities for the care, retraining and rehoming of former racehorses. Under the direction of the chairman of the trustees Peter Deal, the RoR has become recognised as a vital component of the racing industry.
The Blue Cross was founded in 1897 to care for working horses on the streets of London, and equine welfare still plays a vital role in its work today. The charity rehabilitates and rehomes over a hundred horses and ponies every year at its equine centres in Burford (Oxon) and Rolleston-on-Dove (Staffordshire). A third facility in Northiam (East Sussex) provides rest and retirement for Blue Cross equines.
The University of Nottingham, with funding worth £2.2m, is to carry out a study of the most common cause of Bovine Mastitis in the UK - Streptococcus uberis (S. uberis). If researchers can identify which parts of the bacteria enable the infection their results could lead to the production of an effective vaccine.
James Leigh, Professor of Molecular Bacteriology, who has recently joined the School of Veterinary Medicine and Science, said: "We hope to uncover bacterial antigens of potential use in vaccines aimed at preventing bovine mastitis and provide a detailed understanding of how animals can fight off the disease."
S. uberis is responsible for a significant proportion of clinical mastitis worldwide - but unlike many other bacteria that cause the disease, S. uberis is also in the environment - it is found in pasture and bedding and can even colonise the cow at other body sites with no ill effect - so it is difficult to see how it can be controlled by changes to animal husbandry and milking-time hygiene.
With funding from the Biotechnology and Biological Sciences Research Council (BBSRC) the School of Veterinary Medicine and Science has established research laboratories at the Institute for Animal Health (IAH). The project is being conducted in collaboration with Dr Tracey Coffey's Bovine Genomics group based at IAH and other groups at the Royal Veterinary College, the US Department of Agriculture in the UK and the University of Oxford.
Professor Leigh said: "We will use state-of-the-art molecular technology to determine the differences between strains of S. uberis that can and cannot cause disease. Proteins that are only present in the disease causing strains hold the key to determining which components are essential for infection. We will show which of these proteins are most likely to make an effective vaccine by producing strains of S. uberis which lack the ability to produce each of these proteins; if a strain lacking a particular protein is less able to cause disease then this protein is important for the disease process and becomes a candidate for vaccine development."
The team also want to identify any parts of the immune response in the dairy cow which can be altered to prevent the disease - this information could subsequently be used to develop drugs that interfere with the chemical messages that lead to inflammation and therefore reduce the level of disease.
Researchers at the Royal Veterinary College (RVC) have developed a system that eliminates the need for antibiotics and resistance genes in the engineering of industrial and medical products.
The method involves safer, less costly alternatives and is well suited for industrial production of many biofuels and biopharmaceuticals. This research has been published in the online access journal BMC Biotechnology.
Genetic engineering underpins much of biotechnology, and antibiotic selection of engineered strains is a key tool. Unfortunately, antibiotic selection methods risk spreading resistance traits, particularly as biotechnology products move into the environment and clinic. There have been alternatives, but none are satisfactory for wide application.
Gene targeting is the insertion of DNA into specific sites or genes within the genome of selected cells in order to alter gene expression for a particular purpose.
While working on gene targeting in bacteria, RVC researchers discovered that a well-known interaction between a cell membrane synthesis gene and the biocide triclosan could be exploited for strain selection. Surprisingly, triclosan selection performs better than conventional antibiotic selection.
"We think this simple technology is well suited for industrial scale fermentations that produce a range of valuable products, including bio-fuels and bio-pharmaceuticals," said Dr Liam Good, at the Royal Veterinary College and lead researcher on the project. "More importantly, the new system is relatively safe and inexpensive, because the gene is native in all bacteria and triclosan is approved for use in many household applications."
The research was carried out with Dr Shan Goh of the Department of Cell and Molecular Biology, Karolinska Institute, Stockholm.
Pfizer Animal Health has confirmed that the agreement to acquire multiple product franchises from the Schering-Plough Corporation has been completed - and approved by the European Commission. Pfizer has acquired these assets for approximately euro 116 million in cash.
The agreement covers all European Union countries and the franchises include all major animal health species including cattle, swine, equine and companion animal. Pfizer executives say the agreement leaves them with the most in-depth coverage of therapeutic areas, and the most highly recognised brands, in the industry. Precise details of the agreement are not being released although additional information on the products concerned will be the subject of further announcements in due course.
Pfizer has acquired certain rights to the following products in the European Economic Area:
Albert Bourla, President of Pfizer Animal Health in Europe, said: "This represents a significant expansion of our product portfolio and strengthens our long term commitment not just to veterinary surgeons, but also to farmers and pet owners. Pfizer spends hundreds of millions of dollars on research and development every year, and brings more new products to market than any other company, but when the opportunity arose to add well known, well respected brands to a portfolio that is already extremely strong, we had little hesitation in taking it."
Defra has announced the detection of Bluetongue in 18 imported cattle on premises near Bishop Auckland, County Durham. The animals originated from within the BTV8 Restricted Zone in Germany and were detected as a result of post-import testing carried out by Defra on all Bluetongue susceptible animals arriving from Continental Europe.
This is the fourth incidence of infected animals being imported to the UK. Alongside the premises in East Sussex, Hertfordshire and Devon identified in August, the imported animals will remain under restrictions.
As of 1 September the whole of England and Wales is now in a Protection Zone and approximately 30 million doses of vaccine have so far been made available to farmers throughout England and Wales to protect their stock. However, it may take up to six to eight weeks from now for livestock keepers in the North of England and Wales to have had sufficient opportunity to vaccinate their livestock and to gain immunity (at least three weeks in sheep, and six weeks in cattle).
To allow livestock keepers in those areas sufficient opportunity to protect their animals, and while further veterinary investigations are carried out, these particular infected animals will remain under restriction until late October. Any further positive import cases detected may also be restricted for a period of time depending on veterinary risk assessment, while vaccination continues.
Deputy Chief Veterinary Officer, Alick Simmons said: "This incident shows how important it is for farmers to consider potential disease risks when buying stock, regardless of source. Buyers need to consider how best to protect their own businesses and those of their neighbours and make sure they are clear about the stock they are intending to buy.
"I also want to remind farmers about the importance of vaccination. It is the only effective tool to protect susceptible animals from Bluetongue. Recent evidence indicates a drop or delay in vaccine take-up in counties recently brought into the Protection Zone. Sales data for some of those counties suggest that the number of animals vaccinated in these areas could be as low as one in three, and in Northumberland and Cumbria, the most recent counties brought into the Protection Zone, as low as one in five.
"The threat from Bluetongue is present and real, as shown by the most recent import cases. Vaccination as a preventive measure is therefore more important than ever, so the message to the industry remains clear: don't hesitate, vaccinate".
The first coxib for the treatment of osteoarthritis (OA) in dogs, PREVICOX® (Merial), has now been licensed for the relief of post-operative pain and inflammation following soft tissue surgery.
"PREVICOX is the first coxib specifically designed for dogs, and now vets have another reason to use it," said product manager Claire Parry-Baggott. "In addition to the osteoarthritis claim, it is now also proven for use following soft tissue surgery with no adverse effect on bleeding times, haematology or biochemistry.
She added: "With its rapid onset of action and once daily dosing vets can prescribe PREVICOX with confidence at a dose rate of 5mg/kg, two hours pre-surgery and for up to three days including the day of surgery".
To help practice staff explain the importance of the owner's role in after surgery care, and the benefits of using PREVICOX, Merial has produced a practice guide for dog owners following soft tissue surgery. The guide deals with all areas of surgery aftercare including dietary advice, post surgery exercise and wound care. For copies, please contact your local Merial Territory Manager, or call 0870 6000 123.
Merial has launched a new website where you can test your NSAID knowledge and get the chance to win a £50 book voucher. There’s a new winner every month.
The website, http://www.osteoarthritisindogs.co.uk is designed to help practice staff understand more about canine osteoarthritis (OA) and effective management of the condition. The site covers every aspect of canine OA, including treatments and non-pharmacological management strategies. There is also a section for dog owners where practice staff can direct their customers for further information.
Merial product manager Claire Parry-Baggott said: “The practice section is password protected but registration is quite straightforward. The test itself consists of 10 multi-choice questions and your test results are returned within a matter of a few seconds.”
Claire added: "Canine osteoarthritis is a challenging area on its own but is further complicated by the choice of NSAIDs that serve the market. All NSAIDs inhibit the COX-2 enzyme which plays the key role in the development of pain and inflammation. However, traditional NSAIDs also inhibit COX-1 to widely varying degrees. This is a beneficial enzyme that plays an important role in normal physiological functioning. The resulting unwanted side-effects of COX-1 inhibition may hinder therapy, however this is not yet recognised by many vet practices.
“This site will help vets and practice staff better understand canine OA, whilst giving a clearer picture of how different NSAID’s interact with COX-1 and COX-2. The new generation NSAID – firocoxib (Previcox®), selects COX-2 whilst sparing COX-1 and so is a real step forward in the treatment of canine OA.”
Boehringer Ingelheim has announced the results of an independent three-year study which demonstrates that dogs suffering from the most common type of heart failure lived longer (average time in the study of 267 days vs. 140 days) when treated with the product Vetmedin (pimobendan) compared with the ACE inhibitor benazepril hydrochloride.
According to Boehringer, results from the QUEST (Quality of Life and Extension of Survival Time) study, published in the September/October 2008 issue of the Journal of Veterinary Internal Medicine, mark a significant milestone in canine cardiac health.
25% of all small to medium-sized dogs over the age of seven are likely to suffer from heart disease at some point in their life, and 75% of those cases are caused by myxomatous mitral valve disease (MMVD), sometimes known as "valvular insufficiency" or "endocardiosis".
Adrian Boswood from the Royal Veterinary College, London, a Veterinary Cardiology Specialist and a lead-investigator on the study, said: "With QUEST demonstrating that dogs treated with Vetmedin live on average nearly twice as long as those on benazepril, it is now time for us as veterinary cardiologists and practising veterinarians to look again at how we are treating our patients suffering from this serious condition."
Dr. Michael O'Grady from the Ontario Veterinary College, University of Guelph, a fellow lead-investigator added, "The QUEST study provides compelling evidence that dogs with the most common form of heart failure should be receiving Vetmedin® as an essential part of their treatment regimen."
QUEST is the largest international study ever conducted looking at treatment for congestive heart failure (CHF) caused by MMVD, with 260 dogs studied in 11 countries, across three continents, over a period of three years.
The study was conducted by a team of 32 independent veterinary cardiologists from Australia, Canada, France, Germany and the United Kingdom among other countries.
For more information on the QUEST study and on CHF caused by MMVD, see http://www.questtrial.com/
Emily Holbrook MRCVS, Garth Tozer MRCVS, Dr Richard Dixon and Ken Davison MRCVS have all won a Best Practice Employer Award from Novartis Animal Health after glowing nominations from the staff at their practices.
In addition, Katherine Corbett VN from Nine Lives Veterinary Centre won a special new award, worth £500, for the veterinary nurse that in the judges' opinion had best used the opportunities given to her by her boss, Emily Holbrook.
Katherine's first question when told of her win really demonstrates the commitment that veterinary nurses will give a good boss: "Can I spend it on buying one of Kruuse's Buster ICU cages for the practice? Emily has given me so much; I'd love to give something back."
Rachel Smithson, Marketing Manager at Novartis said: "All of our winners were asked what steps they take to ensure a happy team. Their answers were almost unanimous. Empower your staff. Give them responsibility, and if that means accepting the occasional mistake, then do so. Praise them for a job well done. Thank them regularly. Not only will it make your practice a better working environment, but as Katherine demonstrates, your staff will probably go to extraordinary lengths to support you. That translates into a more profitable practice, and higher standards of veterinary care."
The story is covered in full in the August and September editions of Veterinary Practice magazine, downloadable from www.vetsurgeon.org
Sarah Palmer (left) of Novartis Animal Health makes the presentation to head nurse Katherine Corbett and veterinary surgeon Emily Holbrook of Nine Lives Veterinary Practice; behind them are Anne Corbett (receptionist), Lindsay Harrison (nursing assistant), and Laura Steele (veterinary surgeon).
Kenneth Agnew from Novartis Animal Health prepares to present Kenneth Davison with his Best Practice Employer Award, whilst the team toast their boss.
Veterinary Nursing Assistant Abby Brown (left) and Abby Roberts from Novartis Animal Health toast Garth Tozer, Novartis Best Practice Employer Award winner.
Donna Lewis (BVNA), and Novartis Animal Health CEO George Gunn present Dr Richard Dixon with his award.
In the most recent Petplan Pet Census, an annual study of pet ownership in the UK, 97% of vets reported that a lack of funds had led to owners choosing euthanasia over treatment.
Whilst some cases are the result of one-off ‘emergency' treatment, manageable long-term conditions are often at the root of much unnecessary euthanasia because owners simply cannot afford the cost of ongoing treatment. Reported increases in pet obesity and diabetes, arthritis and behavioural problems have all been cited in the Pet Census as common causes of increased and ongoing vet bills.
Vets have been reporting a rise in diseases that are related to obesity in companion animals for some time and with the Petplan Pet Census panel of almost two hundred (198) UK veterinary practices reporting that more than one third (36%) of all dogs and one quarter (29%) of cats they treat are obese, the future for many pets looks bleak. More than half (53%) of vets say that cases of cat and dog diabetes are on the increase. Obesity is actually bucking the trend of more historically significant diseases, including kennel cough and feline leukaemia, which are either remaining static or decreasing.
The number of pets with behavioural problems is also on the rise, with more than half of vets (55%) reporting an increase and most (95%) practices offering support for these animals. Effective treatment is not a quick-fix solution and requires changes to the owner's lifestyle and lengthy work with experts in the field.
Petplan Vet of the Year, Brian Faulkner said: "I think it is a common misconception that the predicament forcing pet owners to euthanase their pet is the out-of-the-blue, one-off vet fees for emergencies. But in fact we are noticing that owners whose pets have on-going illnesses such as diabetes and even behavioural problems that are very manageable are being faced with the dreadful decision to have to euthanase than face the ongoing financial burden. It's even more devastating when the owners have actually taken out an insurance policy but the nature of the policy only covers treatment of any one condition for up to one year. I always advise people to make sure their policies do not cap the time period over which any one condition is covered to avoid this very problem as more comprehensive insurers are then unable to offer cover on a pre-existing condition."
Simon Wheeler, Head of Marketing at Petplan, said: "We receive over 8,700 claims per week and of the top ten claims, six could be recurrent manageable conditions, such as diabetes or arthritis - the very animals that are currently most at risk of being euthanased."
Research announced simultaneously by Sainsbury's Finance has reached similar conclusions. Sainsbury's found that:
Sainsbury's believes that there are two main reasons for this tragic problem: advances in veterinary care leading to increased costs, and the large number (55%) of pets that remain uninsured.
Ed's note: Isn't it time that pet insurance became compulsory?
Epiphen, Vétoquinol's canine anti-epileptic drug, has been re-launched with new packaging and a useful dosing syringe.
"Some of our customers reported that they were having difficulty administering the drops accurately," explains Slavica Sobot, Product Manager. "So with this in mind, we have introduced a new plug-on syringe which will make it even easier for pet owners to dose accurately. The syringe will prevent the risk of inaccurate dosing through ‘flooding' from the dropper."
For more information, please call the Vétoquinol help line on 0800 169 8197 or contact your Vétoquinol representative.
The invaluable work done by equestrian vets in the UK is to be recognised with a new award sponsored by leading equine insurance provider Petplan Equine at the Animal Health Trust Awards in November. The ‘Petplan Equine Vet of the Year' award people's vote will reflect the huge contribution made by vets to the equine community.
Owners and riders will be able to nominate their equine vet for the award if they feel that they are deserving of the recognition that this accolade would bring. Veterinary practice personnel are also encouraged to nominate a colleague who they feel has gone beyond the call of duty. Leaflets have been sent to practices across the UK outlining how to nominate and people can also register through the Petplan Equine website www.petplanequine.co.uk. A short list will be drawn up from the nominations received and an independent panel will decide the winner, who will receive his or her award at the Animal Health Trust Equestrian Awards in London on November 6th 2008.
This year marks the 20th anniversary of the Animal Health Trust Equestrian Awards, which recognise the outstanding achievements made by horses, riders, owners and trainers throughout the equestrian world. This milestone coincides with Petplan Equine's 20th anniversary and, since 1994 when the Petplan Equine Charitable Trust was founded, it has raised over £5 million, almost £500,000 of which has been donated to the AHT to fund research and development.
Jo Whitaker of Petplan Equine says: "It has been a privilege to be involved with the AHT Awards over the years and we look forward to this exciting 20th anniversary year. Petplan Equine has sponsored the Eventing Award for the past three years but this new award will recognise the commitment and hard work of people within the equine veterinary profession and the service they provide to horse owners. Horse welfare is paramount at Petplan Equine and we are committed to promoting responsible horse ownership, through our wide range of policies, our charitable contributions and our Horse Handbook. This award will give the equine community the opportunity to acknowledge and celebrate the vet who has made the most outstanding contribution to the care of horses."
To nominate go to www.petplanequine.co.uk. The closing date for nomination is 3rd October 2008.
The Society of Practising Veterinary Surgeons (SPVS) has published advice to help practitioners set realistic and reasonable script fees for POM-V medicines.
The document, which is now available to all practitioners via the SPVS web site (www.spvs.org.uk) or can be emailed or posted upon request, has been produced following extensive consultation with SPVS members, principally via the Society's active and influential discussion list, and in conjunction with the BVA Medicines Group, which backs the advice.
The document constitutes a valuable framework for practitioners in calculating a prescription fee that is fair and workable for clients wanting a written prescription as well as for those who do not want a prescription issuing. Furthermore, it also provides a framework that is fair to practitioners themselves.
The Society firmly believes that the act of preparing and providing a prescription is a professional service and as such, that it should attract a professional fee.
Richard Hillman, SPVS President, explained: "We welcome whole-heartedly the re-introduction of prescription fees, which will mark the end of a bureaucratic and fundamentally unfair sitituation for many thousands of small businesses that have had their trade and profitability restricted for three long years.
"The time element involved in writing subscriptions will need to be taken into account, and this will no doubt form a sensible basis on which to base a fee. Script fees should be calculated rationally to reflect true business costs, like any other service that a business provides to its customers."
He added: "We would, above all else, urge practitioners to exercise restraint in setting script fees, as it is by no means certain that they will still be in place even two years from now. We will also not condone any form of 'punishment' of clients taking away prescriptions by punitive fees. We are already cooperating with the RCVS as they work with the OFT in the monitoring period to ensure that there is fair competition in the veterinary medicines market."
To obtain your copy of the document Advice on Prescription Fees, go to www.spvs.org.uk where it can be downloaded or call SPVS Secretariat on 01926 410454 or email office@spvs.org.uk.
Veterinary surgeon Noel Fitzpatrick, a pioneer of prosthetic implants, has launched what is being billed as Europe's most advanced neuro-orthopaedic centre for dogs and cats.
Fitzpatrick Referrals' £10m facilities at Eashing, near Godalming, Surrey, have been set up to offer a world-class "centre of excellence" in diagnosis, surgery and rehabilitation.
Facilities at the centre include:
Noel was the first veterinary surgeon to successfully apply a prosthetic limb to a dog where both bone and skin can grow into metal - a technique with far-reaching cross-over potential for human surgery. He believes in "pushing the boundaries" and creating solutions for conditions that may never have previously been treatable, and says the work being done at Eashing also provides valuable experience for medical science as a whole. Examples include cartilage resurfacing, limb-sparing cancer surgery and spinal vertebral fusion.
Professor Gordon Blunn of the Centre for Biomedical Engineering, Institute of Orthopaedics and Musculo-Skeletal Science at University College London said: "Orthopaedic conditions and diseases are common to both human beings and to animals. For example osteoarthritis is debilitating condition seen in humans, cats and dogs. Bone cancer which can lead to loss of life in humans and is usually associated with the peripheral skeleton is also seen in the peripheral skeleton of large dog breeds. Translation of ideas, orthopaedic practice and treatments, from humans to the veterinary field and visa versa has considerable advantages to all animals including dogs, cats and man. Noel Fitzpatrick is pioneering this concept and his work in limb reconstruction for dogs and cats has already had benefits in both veterinary and human orthopaedic practice."
DJ Chris Evans is one satisfied client. His dog, Enzo, a German Shepherd, was "written off" by other vets after becoming paralysed with two herniated discs. Noel fitted Enzo with two bolts to replace the collapsed disc and keep the vertebrae apart. The surgery was followed by extensive physiotherapy and hydrotherapy to enable Enzo to learn to walk again.
Chris said: "Noel lives out his dreams with boundless curiosity, ambition and genius, the product of which is hundreds, soon to be thousands, of fixed pets and happy owners - like me. I have huge respect for his endeavour, his integrity and his compassion and to me he's a superhero-vetman who will leave no stone unturned in his quest to heal, to create and to comfort. He thinks of solutions to medical problems that I'm sure no-one else could even dream of, let alone think of. Actually - I don't think he ever sleeps!"
Centaur Services' veterinary wholesale business has been acquired by AHN International. Centaur was founded in 1964 by a group of veterinary surgeons who wanted to increase their buying power and the range of products available to them. Over the next 44 years the business, which was owned by its veterinary surgeon shareholders, grew to a turnover of nearly £140m. The company has recently completed a 3 year programme of modernisation making it one of the most technologically advanced wholesalers in Europe. In September 2007, Centaur Services announced its intention to list its shares on the Alternative Investments Market (AIM). These plans were initially postponed and finally cancelled when the Centaur shareholders accepted the offer from AHN. Paul Gerring, Centaur Services' Managing Director said: "There has been considerable consolidation in the veterinary market over recent years, particularly amongst manufacturers, and this partnership with AHN provides us with an increased presence in the market. Like Centaur, AHN is a vet-focussed business with plans to be active in the veterinary supply market on a European and global basis. We see plenty of exciting opportunities out there". AHN International was established to form the first global coalition of leading animal health wholesalers and distributors. With nearly 700 employees worldwide, AHN International is committed to presenting the veterinary surgeons with an advanced level of product and services. Headquartered in Raleigh, North Carolina, AHN International will actively build it's network of leading trading companies around the world through acquisitions and business associations.
New and recent graduates and recently qualified vets have the opportunity to attend a CPD graduate symposium specifically designed to provide practical surgical and management advice and solutions for those embarking on their professional careers.
ProStart course director Colin Whiting BVSc CertSAS MRCVS explained: "We're aiming to fast-track new graduates by sharing experience and helping them through that tricky first year in practice. However, whilst the course has a total of 11 hours CPD, it also has a packed fun and social element including zip wire and surf lessons."
Sponsored by Merial Animal Health, the inaugural ProStart CPD graduate symposium is to be held at Lusty Glaze beach adventure and lecture centre, Newquay, Cornwall, Friday 10th to Sunday 12th October 2008.
Mr Whiting said: "The event includes a full-on itinerary of lectures and workshops covering aspects of small animal practice including, practice economics, consultation skills, surgical guides for neutering, maximising therapeutic opportunities, and client and staff interactions - with tips from a head nurse. It's also a great opportunity to network with other new graduates.
"The workshops are run by vets experienced in mentoring new graduates in practice, plus full board & lodging and a vibrant social programme including adventure Zip wire, Surf lesson, and entertainment."
For Merial's Mark Riggs the symposium will help graduates understand the realities of practice environment more quickly. He said: "This course is a neat combination of practical and business skills. Not only will graduates have the chance to sharpen their neutering techniques but advice will be on hand relating to practice finances, client handling and staff management. Delegates will be encouraged to contribute within workshops tackling thorny issues from general practice, before it's wetsuits on and a surf lesson."
Mr Whiting, a referral surgeon and clinical director based at Penmellyn Vet Group in Cornwall has publications and CPD presentations which focus on surgical and practice management topics, and include Surgical Mentoring of Junior Colleagues for In Practice.
"We have a very experienced lecture team, members of which have worked extensively supporting graduates and junior colleagues. Bearing in mind that CPD has to be affordable for practice owners, thanks to our sponsors, Merial, we're able to provide an entire weekend course, including accommodation, for £240+VAT. The venue's proximity to Newquay airport provides easy accessibility for delegates nation-wide and is a fantastic venue for adventure challenges, surfing and various beach activities."
Other members of the ProStart team include Ian Stroud BVSc MRCVS a Medivet partner and new graduate supervisor, and Gareth Cross BVSc, MRCVS who recently lectured to BSAVA congress. Their focus will be promoting safe clinical excellence; illustrating the finances behind a small animal practice; and how graduates can add to a practice in these areas.
If you would like more information on the course or would like to book a place please contact Beverley Archer; beverly.archer@merial.com, or contact your local Merial Territory Manager.
Vets Now, the Out Of Hours emergency vets has announced the launch of Winchester's first dedicated 24/7 pet ambulance service.
Specifically designed for the comfortable and secure transport of all small animals, the new state-of-the-art ambulance is fully kitted out with the latest in emergency equipment.
After completing a course of rigorous training, the fully trained ‘Petamedics' (the animal equivalent of Paramedics), took to the streets of Winchester earlier in the month.
Gareth Roscoe, Vets Now Ambulance Service Team Leader said: "This service will make a real difference to animals in a distressed or critical situation. We've responded to a variety of cases over the past few weeks; one of the most recent ones being a nine week old puppy who was receiving emergency treatment at the Vets Now clinic in Winchester after his owner accidentally fell on him. Charlie was brought to the clinic collapsed and unresponsive with signs of head trauma. The vets set up an intensive treatment plan for him and by the morning, he was almost back to normal and we took him back to his daytime vet.
"The ambulance service provides owners in the Winchester area with the safest and fastest method of transporting their pets to get medical treatment twenty-four hours a day, seven days a week. What's more, the service is also available to owners who have routine transportation problems; so whether owners and their pets are visiting their clinic for a veterinary appointment, attending a referral centre or even going to the groomers, the Vets Now Ambulance offers them a reliable solution to all their pet transportation needs."
The ambulance is a significant new addition to the already established Vets Now Emergency Clinic which is based at the Mildmay Veterinary Centre, Easton Lane in Winchester. Caroline Hirst, Senior Veterinary Surgeon at the emergency clinic commented; "The dedicated 24 hour ambulance has already been called out to help several of our clients ahead of its official media launch on 25 September. As an emergency clinic, we often admit patients overnight, and a real plus of having the ambulance is that we can ensure that pets can be returned to their regular vet or back to their owner in the morning safely and with the minimum of fuss. From experience, Vets Now knows that there are regular occasions when owners are afraid to move their pet if it is unwell or has been involved in an accident. We hope that being able to offer the ambulance service will be of great benefit not only to pets but also to owners, giving them peace of mind that their pet is being cared for and transported in a safe environment until it receives the necessary veterinary treatment at the clinic."
Cover starts from just £1 a week per employee, a very affordable choice for employee healthcare cover. Employees will have access to six healthcare benefits and services, including money back towards their everyday healthcare treatments, such as
For further information visit www.bva.co.uk/membership/benefits/westfield_health.asp
The Horse Trust is funding a three-year project to develop a genetic diagnostic test for Fell Pony Syndrome (FPS) and thus enable control and possible elimination of the disease.
The work will be undertaken at the Animal Health Trust, Newmarket, and the University of Liverpool Veterinary School.
The Fell pony, an ancient British pony breed categorised as "at risk" by the Rare Breeds Survival Trust, has over the past decade or so been subject to a severe immune deficiency known as Fell Pony Syndrome (FPS), which results in the death of some of the newborn foals.
Foals affected with FPS appear normal at birth but within a few weeks begin to lose condition and suffer diarrhoea, coughing and weight loss. Severe anaemia and immune dysfunction follows, leading to wasting and finally death. The disease is always fatal.
As a large percentage of these ponies live and breed on the fell, the prevalence of FPS is unclear. Despite an improvement in foal registration numbers in recent years, Fell Pony Syndrome remains of concern to breeders.
Studbook analysis and knowledge of affected foals strongly suggests that this is an inherited disease caused by an autosomal recessive genetic mutation. A DNA based test for this mutation would enable carriers of FPS to be identified and the conception of affected foals prevented.
As well as identifying carriers in the Fell pony population, the project will be used to identify any carriers in other breeds which have been involved in the extensive outbreeding of Fell ponies over the years.
"The success of this project will prevent the suffering of newborn Fell pony foals affected with FPS," says project leader Dr June Swinburne, senior post- doctoral equine molecular geneticist at the Animal Health Trust Centre for Preventive Medicine. "Foals affected by the condition inherit an incurable genetic defect which results in severe wasting and a profound anaemia together with multiple infections. Veterinary intervention is in vain and once the condition is diagnosed foals are often euthanased. The gradual but relentless decline in these foals leaves both veterinary surgeons and breeders powerless.
"Breeders are supportive of our attempt to develop a diagnostic test which will help to prevent carrier-carrier matings, one in four of which results in an affected foal."
The Horse Trust's Chief Executive and resident veterinary surgeon Paul Jepson said: "This is an exciting and achievable project with significant benefits for equine health and welfare, as it will lead to the prevention and elimination of a fatal disease."
CEVA Animal Health is giving away a key ring torch with every three bottles of Rehydion gel®, its product for scouring calves.CEVA says the deal is to highlight the fact that Rehydion gel® is currently the only oral rehydration treatment that can be added to milk, with guaranteed milk clotting. According to the company, Rehydion gel® has faster, guaranteed milk clotting and helps to maintain a low abomasal pH. Its high palatability and efficient dilution in milk allows weight gain to continue, even in cases of severe scour. It also has a high Strong Ion Difference (SID) which effectively suppresses acidosis. Rehydion gel® is fast to mix by simply shaking the hand-held bottle. Rehydion gel's® consistency means that precise doses of alkalinising agents and electrolytes can be squeeze-delivered with ease. In beef systems the product is time-saving, convenient and minimises stress as it can be given neat, meaning there is need for the calf to be separated from its dam. One bottle provides enough for eight, two-litre calf feeds or 160 feeds for lambs. The distinctive yellow top also acts as a handy measuring cap.
Further information and product literature is available from Martin Gough on 01494 781510.
Following an outdoor advertising campaign that ran earlier this year, Drontal has launched a new national campaign, which will see the iconic Schnauzer featured on over 6,000 outdoor sites across England, Scotland and Wales.
Drontal product manager, Dan White said: "The last Drontal outdoor advertising campaign was a huge success in driving pet-owning clients into practices and we're hoping to build on this with our new advertising push.
"Approximately, 20% of the new advertising sites will be located within a 500 metre radius of veterinary practices serving to drive pet owners to visit local practices to purchase Drontal. We're not only highlighting the benefits of regular worming which results in healthier cats and dogs, but we're also improving the health of practice business."
For further information on Drontal, please contact your Bayer territory manager.